We are analyzing https://link.springer.com/article/10.1007/s00109-007-0221-2.

Title:
Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome | Journal of Molecular Medicine
Description:
The p53 tumor suppressor protein has long been recognized as the central factor protecting humans from cancer. It has been famously dubbed “the guardian of the genome” due to its ability to respond to genotoxic stress, such as DNA damage and other stress signals, and to protect the genome by inducing a variety of biological responses including DNA repair, cell cycle arrest, and apoptosis. However, the tumor suppressive effects of p53 go far beyond its roles in mediating these three processes. There is growing evidence that p53 also exerts its effects on multiple aspects of tumor formation, including suppression of metastasis and, as summarized in this review, inhibition of new blood vessel development (angiogenesis). The p53 protein has been shown to limit angiogenesis by at least three mechanisms: (1) interfering with central regulators of hypoxia that mediate angiogenesis, (2) inhibiting production of proangiogenic factors, and (3) directly increasing the production of endogenous angiogenesis inhibitors. The combination of these effects allows p53 to efficiently shut down the angiogenic potential of cancer cells. Inactivation of p53, which occurs in approximately half of all tumors, reverses these effects; as a consequence, tumors carrying p53 mutations appear more vascularized and are often more aggressive and correlate with poor prognosis for treatment. Thus, the loss of functional p53 during tumorigenesis likely represents an essential step in the switch to an angiogenic phenotype that is displayed by aggressive tumors.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,626,432 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com could have a money-making trick up its sleeve, but it's undetectable for now.

Keywords {🔍}

pubmed, google, scholar, cas, article, cancer, angiogenesis, tumor, cell, growth, thrombospondin, res, factor, biol, cells, human, gene, endothelial, type, expression, protein, carcinoma, inhibition, hypoxia, vascular, nat, regulation, mol, bouck, role, suppressor, apoptosis, access, inhibitor, science, oncogene, collagen, genome, prolyl, cyclooxygenase, nature, rev, folkman, lawler, chem, usa, antiangiogenic, volpert, kalluri, privacy,

Topics {✒️}

transforming growth factor-beta-dependent brain-specific p53-target gene month download article/chapter node-negative breast carcinoma tumor suppressor-dependent inhibitor p53 tumour suppressor endothelium-specific tumor suppressors bfgf-binding protein expression p53-family proteins hypoxia-inducible factor 1alpha neck squamous-cell carcinoma cell cycle arrest ras-transformed epithelial cells tumor suppressor gene p53-mediated proteasomal degradation molecular biology full article pdf lewis lung carcinoma hypoxia-inducible factor 1 related subjects human collagen xv collagen prolyl hydroxylase o2-regulated prolyl hydroxylation privacy choices/manage cookies endogenous angiogenesis inhibitors epha2 tyrosine kinase hypoxia induces accumulation host–tumor interaction human prostatic carcinoma p53 protein expression tumour angiogenesis anti-angiogenic activity anti-angiogenic cues p53-dependent transactivation tgf-beta signaling increase tumor angiogenesis occult papillary carcinoma cyclooxygenase-2 gene expression medical foundation charles massachusetts medical school check access instant access hepatocellular carcinoma cells matrix protein thrombospondin-1 hypoxia-mediated selection viral myc oncoproteins myc oncoprotein leads caspase death pathway tumor microvessel density matrix-derived inhibitor

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome
         description:The p53 tumor suppressor protein has long been recognized as the central factor protecting humans from cancer. It has been famously dubbed “the guardian of the genome” due to its ability to respond to genotoxic stress, such as DNA damage and other stress signals, and to protect the genome by inducing a variety of biological responses including DNA repair, cell cycle arrest, and apoptosis. However, the tumor suppressive effects of p53 go far beyond its roles in mediating these three processes. There is growing evidence that p53 also exerts its effects on multiple aspects of tumor formation, including suppression of metastasis and, as summarized in this review, inhibition of new blood vessel development (angiogenesis). The p53 protein has been shown to limit angiogenesis by at least three mechanisms: (1) interfering with central regulators of hypoxia that mediate angiogenesis, (2) inhibiting production of proangiogenic factors, and (3) directly increasing the production of endogenous angiogenesis inhibitors. The combination of these effects allows p53 to efficiently shut down the angiogenic potential of cancer cells. Inactivation of p53, which occurs in approximately half of all tumors, reverses these effects; as a consequence, tumors carrying p53 mutations appear more vascularized and are often more aggressive and correlate with poor prognosis for treatment. Thus, the loss of functional p53 during tumorigenesis likely represents an essential step in the switch to an angiogenic phenotype that is displayed by aggressive tumors.
         datePublished:2007-06-23T00:00:00Z
         dateModified:2007-06-23T00:00:00Z
         pageStart:1175
         pageEnd:1186
         sameAs:https://doi.org/10.1007/s00109-007-0221-2
         keywords:
            p53 tumor suppressor protein
            Tumor biology
            Hypoxia
            Collagen
            Angiogenic switch
            Angiogenesis inhibitors
            Molecular Medicine
            Human Genetics
            Internal Medicine
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00109-007-0221-2/MediaObjects/109_2007_221_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00109-007-0221-2/MediaObjects/109_2007_221_Fig2_HTML.gif
         isPartOf:
            name:Journal of Molecular Medicine
            issn:
               1432-1440
               0946-2716
            volumeNumber:85
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Jose G. Teodoro
               affiliation:
                     name:McGill University
                     address:
                        name:McGill Cancer Centre and Department of Biochemistry, McGill University, Montreal, Canada
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Sara K. Evans
               affiliation:
                     name:University of Massachusetts Medical School
                     address:
                        name:Howard Hughes Medical Institute, Programs in Gene Function and Expression and Molecular Medicine, University of Massachusetts Medical School, Worcester, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Michael R. Green
               affiliation:
                     name:University of Massachusetts Medical School
                     address:
                        name:Howard Hughes Medical Institute, Programs in Gene Function and Expression and Molecular Medicine, University of Massachusetts Medical School, Worcester, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Inhibition of tumor angiogenesis by p53: a new role for the guardian of the genome
      description:The p53 tumor suppressor protein has long been recognized as the central factor protecting humans from cancer. It has been famously dubbed “the guardian of the genome” due to its ability to respond to genotoxic stress, such as DNA damage and other stress signals, and to protect the genome by inducing a variety of biological responses including DNA repair, cell cycle arrest, and apoptosis. However, the tumor suppressive effects of p53 go far beyond its roles in mediating these three processes. There is growing evidence that p53 also exerts its effects on multiple aspects of tumor formation, including suppression of metastasis and, as summarized in this review, inhibition of new blood vessel development (angiogenesis). The p53 protein has been shown to limit angiogenesis by at least three mechanisms: (1) interfering with central regulators of hypoxia that mediate angiogenesis, (2) inhibiting production of proangiogenic factors, and (3) directly increasing the production of endogenous angiogenesis inhibitors. The combination of these effects allows p53 to efficiently shut down the angiogenic potential of cancer cells. Inactivation of p53, which occurs in approximately half of all tumors, reverses these effects; as a consequence, tumors carrying p53 mutations appear more vascularized and are often more aggressive and correlate with poor prognosis for treatment. Thus, the loss of functional p53 during tumorigenesis likely represents an essential step in the switch to an angiogenic phenotype that is displayed by aggressive tumors.
      datePublished:2007-06-23T00:00:00Z
      dateModified:2007-06-23T00:00:00Z
      pageStart:1175
      pageEnd:1186
      sameAs:https://doi.org/10.1007/s00109-007-0221-2
      keywords:
         p53 tumor suppressor protein
         Tumor biology
         Hypoxia
         Collagen
         Angiogenic switch
         Angiogenesis inhibitors
         Molecular Medicine
         Human Genetics
         Internal Medicine
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00109-007-0221-2/MediaObjects/109_2007_221_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00109-007-0221-2/MediaObjects/109_2007_221_Fig2_HTML.gif
      isPartOf:
         name:Journal of Molecular Medicine
         issn:
            1432-1440
            0946-2716
         volumeNumber:85
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Jose G. Teodoro
            affiliation:
                  name:McGill University
                  address:
                     name:McGill Cancer Centre and Department of Biochemistry, McGill University, Montreal, Canada
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Sara K. Evans
            affiliation:
                  name:University of Massachusetts Medical School
                  address:
                     name:Howard Hughes Medical Institute, Programs in Gene Function and Expression and Molecular Medicine, University of Massachusetts Medical School, Worcester, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Michael R. Green
            affiliation:
                  name:University of Massachusetts Medical School
                  address:
                     name:Howard Hughes Medical Institute, Programs in Gene Function and Expression and Molecular Medicine, University of Massachusetts Medical School, Worcester, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Journal of Molecular Medicine
      issn:
         1432-1440
         0946-2716
      volumeNumber:85
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:McGill University
      address:
         name:McGill Cancer Centre and Department of Biochemistry, McGill University, Montreal, Canada
         type:PostalAddress
      name:University of Massachusetts Medical School
      address:
         name:Howard Hughes Medical Institute, Programs in Gene Function and Expression and Molecular Medicine, University of Massachusetts Medical School, Worcester, USA
         type:PostalAddress
      name:University of Massachusetts Medical School
      address:
         name:Howard Hughes Medical Institute, Programs in Gene Function and Expression and Molecular Medicine, University of Massachusetts Medical School, Worcester, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Jose G. Teodoro
      affiliation:
            name:McGill University
            address:
               name:McGill Cancer Centre and Department of Biochemistry, McGill University, Montreal, Canada
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Sara K. Evans
      affiliation:
            name:University of Massachusetts Medical School
            address:
               name:Howard Hughes Medical Institute, Programs in Gene Function and Expression and Molecular Medicine, University of Massachusetts Medical School, Worcester, USA
               type:PostalAddress
            type:Organization
      name:Michael R. Green
      affiliation:
            name:University of Massachusetts Medical School
            address:
               name:Howard Hughes Medical Institute, Programs in Gene Function and Expression and Molecular Medicine, University of Massachusetts Medical School, Worcester, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:McGill Cancer Centre and Department of Biochemistry, McGill University, Montreal, Canada
      name:Howard Hughes Medical Institute, Programs in Gene Function and Expression and Molecular Medicine, University of Massachusetts Medical School, Worcester, USA
      name:Howard Hughes Medical Institute, Programs in Gene Function and Expression and Molecular Medicine, University of Massachusetts Medical School, Worcester, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(294)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.68s.

LINK . SPRINGER . COM {}